Wells Fargo & Company Galecto, Inc. Transaction History

Wells Fargo & Company

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.6 - $0.89 $1 - $2	3 Added 1.97%	155 $0
Q4 2023 Feb 09, 2024	SELL	$0.52 - $0.78 $167 - $251	-322 Reduced 67.93%	152 $0
Q3 2023 Nov 13, 2023	SELL	$0.56 - $3.17 $1,137 - $6,438	-2,031 Reduced 81.08%	474 $0
Q2 2023 Aug 15, 2023	BUY	$1.68 - $2.84 $10 - $17	6 Added 0.24%	2,505 $6,000
Q1 2023 May 12, 2023	BUY	$1.21 - $2.86 $2 - $5	2 Added 0.08%	2,499 $4,000
Q4 2022 Feb 13, 2023	SELL	$1.06 - $58.5 $526 - $29,074	-497 Reduced 16.6%	2,497 $2,000
Q3 2022 Nov 14, 2022	BUY	$1.59 - $60.0 $12 - $480	8 Added 0.27%	2,994 $5,000
Q2 2022 Aug 12, 2022	BUY	$1.22 - $2.74 $10 - $24	9 Added 0.3%	2,986 $5,000
Q4 2021 Feb 14, 2022	SELL	$2.3 - $3.58 $16,518 - $25,711	-7,182 Reduced 70.7%	2,977 $9,000
Q3 2021 Nov 15, 2021	SELL	$3.59 - $5.0 $125,273 - $174,475	-34,895 Reduced 77.45%	10,159 $36,000
Q2 2021 Aug 16, 2021	BUY	$4.63 - $8.0 $208,424 - $360,128	45,016 Added 118463.16%	45,054 $228,000
Q1 2021 May 13, 2021	BUY	$6.08 - $13.25 $231 - $503	38 New	38 $0

21.2K

Ticker GLTO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,395,700
Market Cap $143M
Description
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.